Cattle producers and veterinarians now have a new option for control of Bovine Respiratory Disease (BRD) in beef and non-lactating dairy cattle at high risk of developing BRD. Baytril 100 (enrofloxacin) Injectable, manufactured by Bayer HealthCare LLC, Animal Health Division, has been approved by the FDA for control of all four major BRD pathogens. With the latest approval from FDA, Bayer HealthCare asserts that Baytril 100 is the first and only fluoroquinolone approved for treatment of BRD and control of BRD in high-risk cattle.

Baytril 100 is for the treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non‑lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy heifers less than 20 months of age at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.

BRD has a significant health and economic impact on cattle operations across the country. Particularly susceptible are cattle at high risk of developing infections due to stress from travel and co-mingling with other cattle.

“With the approval of Baytril 100 for control of BRD in high-risk cattle, there is greater flexibility for the management of BRD — whether it is a metaphylaxis or treatment scenario,”said Dan Thomson of the Beef Cattle Institute, Kansas State University.

In the lab, Baytril 100 kills 97 percent of the key BRD-causing bacteria in one to two hours, in vitro.* In a clinical field study, Baytril 100 demonstrated statistically significant control of BRD in high-risk cattle in a 14-day study.

Advertisement

Available in 100 mL, 250 mL and 500 mL bottles, Baytril 100 has been a choice for many bovine veterinarians and cattle producers since its introduction in 1998 and is the largest-selling, single-dose antibiotic in its class. The first FDA-approved fluoroquinolone antimicrobial for use against BRD, Baytril 100 is a proven and effective BRD antimicrobial.

*The clinical significance of in vitro data has not been demonstrated.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Extra-label use of this product in food-producing animals is prohibited. Cattle intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. PD

—From Bayer HealthCare news release